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ABSTRACT
Objectives: To understand how older adults perceive their risk of Alzhe-
imer’s Disease (AD) and how this may shape their medical care decisions,
we examined whether presence of established risk factors of AD is asso-
ciated with individuals’ perceived risk of AD, and with preference for
preventing AD.
Methods: Participants: Data came from the US Health and Retirement
Study participants who were asked questions on AD risk perception
(N = 778). Measurements: Perceived risk of AD was measured by respon-
dents’ estimate of their percent chance (0–100) developing AD in the next
10 years. Preference for AD prevention was measured with questions
eliciting willingness to pay for a drug to prevent AD. Analysis: Multivari-
ate linear regressions were used to estimate correlates of perceived risk and
preference for prevention.
Results: Better cognitive functioning and physical activity are associated
with decreased perceived risk. Neither age nor cardiovascular disease is
associated with perceived risk. African Americans have lower perceived
risk than non-Latino whites; the difference is wider among people age
65 and above. Only 4% to 7% of the variation in perceived risk was
explained by the model. Preference for prevention is stronger with
increased perceived risk, but not with the presence of risk factors. Persons
with better cognitive functioning, physical functioning, or wealth status
have a stronger preference for prevention.
Conclusion: Some known risk factors appear to inform, but only mod-
estly, individuals’ perceived risk of AD. Furthermore, decisions about AD
prevention may not be determined by objective needs alone, suggesting a
potential discrepancy between need and demand for AD preventive care.
Keywords: Alzheimer’s disease, prevention preference, risk perception,
willingness to pay.
Introduction
The prevalence of Alzheimer’s disease (AD) is increasing as the
population ages, and in the United States, it is estimated to rise
from $4.5 million in 2000 to $13.2 million in 2050 [1]. The
growing number of people with AD and the costs associated with
the disease put a heavy economic burden on society. In addition
to direct and indirect costs to the affected individuals and their
caregivers, Medicare costs associated with AD and other types
of dementia amounted to $62 billion in 2000, and are projected
to be 40% of the Medicare budget by 2050 unless new effective
treatments for AD become available [2].
At present, there is no effective treatment for AD, but progres-
sion to severe dementia can be slowed and symptoms managed.
Growing literature suggests that metabolic changes associated
with cardiovascular disease and diabetes may contribute to the
development or the severity of AD [3–6]. In addition, clinical and
epidemiological studies suggest that development of cognitive
impairment could be delayed by addressing modiﬁable lifestyle
factors, such as increasing physical activity [7–11], vegetable
consumption [12], and social andmental activity [13]. Because the
incidence of AD doubles every 5 years from age 65 and beyond
[14], the prevalence and costs of AD might drop by half by
delaying the onset of AD by 5 years with preventive interventions.
Understanding how older adults perceive their risk of AD
and how they may make decisions regarding AD prevention
is a prerequisite for successful implementation of an intervention
to prevent or delay onset of AD. The few studies conducted in the
United States [15], Australia [16], and Israel [17] consistently
demonstrate that people have limited knowledge about risk
factors, symptoms, and treatment options of AD. This suggests
that individuals’ perceived risk of AD may be inaccurate and thus
their ability to make informed decisions regarding AD preventive
care may be limited. None of these published studies examined
the relationship among risk factors, perceived risk, and stated
preference for prevention regarding AD, which is the focus of
our study. Studies on cancer suggest a positive association
between perceived risk and preference for prevention, although
the association was not always consistent [18–23]. Generally,
there is positive association between higher perceived risk
and increased willingness to take screening tests or pay for
preventive programs, but the relationship seems weak or absent
when the treatment options involve potential risk or lifestyle
changes.
To advance our understanding of older adults’ risk perception
for AD and their preferences for AD prevention, the present
study examines the relationship among known risk factors
and other individual characteristics, perceived risk of AD, and
preference for AD prevention, using a nationally representative
sample of US older adults. Findings from this study can inform
policy on setting priorities for current AD prevention programs
as well as on future public health efforts as effective prevention
or treatment options become available. Thus, this article seeks to
answer the following research questions: First, are known risk
factors of AD associated with perceived risk of AD?; Second,
is an individual’s preference for AD prevention, measured by
willingness to pay (WTP) for a hypothetical drug preventing AD,
associated with perceived risk and/or known risk factors of AD?
Address correspondence to: Sukyung Chung, Phillip R. Lee Institute for
Health Policy Studies, University of California, San Francisco, Ames Bldg.
795 El Camino Real. Palo Alto, CA 94301, USA. E-mail: Sukyung.
Chung@ucsf.edu
10.1111/j.1524-4733.2008.00482.x
This study was supported by a pilot grant from the Center for Aging
in Diverse Communities funded by grant No. P30-AG15272 under the
Resource Centers for Minority Aging Research program by the National
Institute on Aging, National Institute of Nursing Research, and the
National Center for Minority Health and Health Disparities.
Volume 12 • Number 4 • 2009
V A L U E I N H E A LT H
450 © 2008, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 1098-3015/09/450 450–458
Methods
Data
We examined data from the Health and Retirement Study
(HRS), a nationally representative survey of US residents age 50
and older in 1992, and their spouses of any age (http://hrsonline.
isr.umich.edu). Latinos and African Americans were over-
sampled. The HRS is the only national survey asking questions
about perceived risk for AD and contains information on cogni-
tive functioning and self-reported measures of a variety of health
conditions, physical functioning, and demographic and economic
status.
Among respondents to the 2002 HRS survey, those who
agreed to answer additional questions (81%) were randomly
assigned to one of 12 sets of additional questions, one of which
focused on risk perception and preference for preventing AD.
Proxy interview respondents and individuals who reported
having a memory-related disease diagnosed by a physician in
the current or the previous interview (conducted 2 years before)
were not eligible to answer these questions. The resulting sample
of adults is likely to be cognitively healthier and may not be
representative of US adults in the age range. Thus, our goal is to
understand risk perception and preference for prevention among
adults without cognitive impairment. In addition, exclusion of
people with a history of memory-related disease might have
improved the quality of the data because cognitive functioning
is associated with measurement error in older adults [24,25].
Among those who were eligible (n = 778), 95% (n = 740) pro-
vided valid answers (neither “do not know” nor “refused”) to
the perceived risk question and 98% (n = 760) provided valid
answers to the prevention preference questions (Fig. 1).
Measures
Dependent variables. Perceived risk of AD was assessed
by asking respondents to give the probability that they would
develop AD in the next 10 years. The exact wording is as follows:
“Of course, no one can know for sure what will happen in the
future, but we would like to know what you think about various
health risks. Using a scale of 0–100 where 0 means no chance and
100 means absolutely certain, what are the chances that you will
develop Alzheimer’s disease in the next ten years?” Based on the
answer for this question, we coded a discrete variable ranging
0–100.
Preference for preventing AD was measured with questions
asking about WTP for a hypothetical drug preventing AD. Par-
ticipants were ﬁrst asked the following question: “Suppose that a
drug were discovered that guaranteed that someone would never
develop Alzheimer’s disease, and that the treatment was 100%
effective as long as a person took one pill every month for the rest
of their life. Suppose further that there are no side effects. Would
you be willing and able to pay $100 per month for such a pill, or
the same amount in higher insurance payments to cover it?” If
the respondent answered yes to this question, a similar question
with the amount of $250 was asked again; and if yes to this
question, the respondent was further asked a similar question
with $1000. If the respondent answered no to the ﬁrst question
(with $100), a similar question with the amount of $25 was
asked; and then if no, the respondent was further asked a ques-
tion with $5. Based on answers to these questions, we created a
six-category ordinal variable ranging from 1 to 6, each indicating
WTP of: 1) <$5; 2) $5–25; 3) $25–100; 4) $100–250; 5) $250–
1000; and 6) $1000.
Known risk factors of AD. Based on our literature review and
expertise, we analyzed known risk factors of AD, including age,
cognitive functioning, cardiovascular disease and risk factors and
level of physical activity. A variety of measures available in the
HRS were used to deﬁne these risk factors as described below.
Age was used as a continuous variable. Given the fact that
the incidence of AD increases drastically after age 65 [14,26],
we initially compared estimates from regressions with different
functional forms of age, including the quadratic form and
various categorical representations. We found that none of these
speciﬁcations ﬁt the data as determined by the signiﬁcance level
(P > 0.1). Furthermore, to examine the interaction effect of age
with the predictors for perceived risk of AD, we conducted
analyses with two subgroups—age up to 64, and 65 or older.
We used a multidimensional measure of cognitive function-
ing, which is the sum of scores on four tests (0–27): immediate
word recall (0–10), delayed word recall (0–10), subtraction
(0–5), and backward count (0–2). This measure shares questions
with two commonly used instruments, the Mini-Mental State
Exam (MMSE), a standard geriatric dementia screen [27], and
the Telephone Interview for Cognitive Status, a revised version of
the MMSE for use over the telephone [28]. Though the cognitive
screen in the HRS has not been directly compared with measures
used in other surveys or dementia diagnosis, several published
studies have examined the screen, demonstrating its internal
consistency and construct validity [29–31]. For immediate and
delayed word recall tests, respondents were asked to recall as
many words as possible from a list of 10 words provided by
the interviewer, ﬁrst immediately after the list of words was
administered and again 5 minutes later. For the subtraction test,
respondents were asked to subtract 7 from 100 ﬁve times. For the
backward count test, respondents were asked to count backward
from 20 to 10; if respondents failed to count correctly, they could
try again. A score of 2, 1, or 0 was given, depending on whether
the respondent counted backward correctly the ﬁrst time, the
A random subsample of 2002 respondents 
(N=1064)
Question on risk perception  
(N=778)
Excluded (n=324) 
• Proxy interview or  
• Memory-related disease in the 
current or the previous interview 
Valid answer to AD risk perception question 
(N=740; 95%)
Invalid answer* (n=38) 
Invalid answer* (n=48) 
Valid answers to preference for prevention 
questions (N=730; 94%) 
Figure 1 Exclusion criteria and analysis sample.
*Those who answered as “Don’t Know” or who
refused answering the question. AD, Alzheimer’s
disease.
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second time, or not at all. Because these scores are highly corre-
lated with each other, we used a composite score rather than
individual scores to avoid high multicollinearity in the regression
analyses.
Cardiovascular diseases included were stroke and heart
attack. Diabetes, which leads to cardiovascular complications,
was included as well. These were measured by dichotomous
variables, each indicating whether individuals have experienced
any of these problems diagnosed by a physician during the past
2 years. Physical activity was dichotomously coded based on
answers to the question: “On average over the last 12 months
have you participated in vigorous physical activity or exercise
three times a week or more? By vigorous physical activity, we
mean things like sports, heavy housework, or a job that involves
physical labor.”
Other covariates. Several measures of cognitive and physical
functioning that may be associated with people’s perceived risk
of AD were also examined. Physical functioning was measured
with a dichotomous variable indicating whether an individual
has any limitation in activity of daily living (ADL). In sensitivity
analyses, we also examined two measures: 1) self-rated memory
decline, a dichotomous variable based on the question: “Com-
pared to (last interview date or two years ago), would you say
your memory is better now, about the same, or worse now than
it was then?;” and 2) longevity expectation, a continuous vari-
able (0–100) based on the question asking the percent chance the
respondent would live the next 10 years.
Variables representing sociodemographic characteristics
included in all analyses were race/ethnicity, education, gender,
and marital status. Four exclusive categories of race/ethnicity:
non-Latino white, African American, Latino, and other race were
used. For the other race category, further information on national
origin is not available in the HRS public use ﬁle. Two dummy
variables were used for educational attainment, indicating less
than high school and college or more, with the referent category
of high school graduation. In addition, three variables indicating
ability to pay—total household income (continuous variable),
total household wealth (continuous variable), and having pre-
scription drug coverage (0/1)—were included for the analysis
of preference for preventing AD. We also examined dummy
variables indicating each quartile of income and wealth distribu-
tion. Except for one missing value in race/ethnicity, valid answers
were reported or veriﬁed for all other covariates.
Analytical Methods
We ﬁrst examined descriptive statistics for all the variables
and then conducted multivariate regression analyses. In order to
model preference for preventing AD as an outcome, we estimated
ordered probit and linear regressions. As we obtained virtually
the same results using both methods, we report the linear regres-
sion results for ease of interpretation. Covariates included in all
the regression models were known risk factors of AD, functional
limitation, and sociodemographic characteristics as described
above. We detected heteroskedasticity based on the White test,
and used Huber–White robust standard errors [32] for all regres-
sion analyses. Sensitivity analyses were conducted to examine the
robustness of the results.
Results
Descriptive Statistics
The average age of the respondents (including individuals from
the original HRS sample and their spouses) was 68, ranging from
31 years to 96 years. The predominant majority of the sample
were in their 50s to 80s (97.2%); a small fraction of the sample
was under 50 (1.4%) or over 90 (1.4%), which consisted entirely
of spouses. Slightly more than half (53%) were women. The
majority was non-Latino white (81%), 11% were African Ame-
rican, and 5% were Latino. The other race/ethnicity group
comprised only 1% (n = 10). See Table 1 for statistics on other
individual characteristics. Because people with a history of
memory-related disease were excluded, the respondents for the
current study were more likely to be young and male than the
overall HRS participants.
The average perceived risk (percent chance) of AD in 10 years
was 29.9 (SD 27.1) and the median preference for AD prevention
was in the third category (willing to pay $100 but not $250
per month) (Table 1). The distribution of perceived risk of AD
ranged from 0 to 100 with two distinctive peaks at 0 (n = 166;
22.4%) and 50 (n = 193; 26.1%) (Fig. 2). We examined whether
the likelihood of providing answers of 0, 50, or 100 was sys-
tematic and was predicted by any of the covariates using logit
Table 1 Descriptive statistics of the analysis sample
Variables*,† Mean [SD] Frequency
Perceived risk of AD in the next 10 years
(in % chance: 0–100)
29.9 [27.1]
Preference for AD prevention: $ willing
to pay per month
<5 6.5%
5–25 7.9%
25–100 19.6%
100–250 37.1%
250–1000 22.0%
>1000 7.0%
Longevity expectation (0–100) 48.9 [32.3]
Self-rated memory decline 19.4%
Known risk factors of AD
Age 68.0 [9.66]
Cardiovascular disease/risk factors
Stroke 5.8%
Heart attack 2.7%
Diabetes 19.0%
Physical activity 41.5%
Cognitive functioning (0–27)‡ 15.1 [4.59]
Immediate recall (0–10) 5.40 [1.79]
Delayed recall (0–10) 4.42 [2.03]
Subtraction (0–5) 3.57 [1.68]
Backward count (0–2) 1.72 [0.70]
Any limitation in ADL 14.9%
Other sociodemographic characteristics
Female 53.2%
Race/ethnicity
White 81.2%
Black 11.2%
Hispanic 6.0%
Other race 1.5%
Education
Less than high school 23.5%
High school graduate 35.6%
Some college 40.7%
Married 67.4%
Prescription drug coverage 74.9%
Household wealth (-$130,000–
$41,639,999)§
391,206 [1,594,994]
Household income (0–$757,000) 51,769
*Range of values for continuous variables is presented in the parentheses.
†Total number of participants was 778. For some variables, the number of participants who
provided valid answers was as follows: perceived risk of AD (n = 740); preference for AD
prevention (n = 760); longevity expectation (n = 714); cognitive functioning (n = 762); and
race/ethnicity and education (n = 777).There was no missing value for other variables.
‡Sum of scores for the four measures in following rows. Nonresponse for each test is
excluded (i.e., coded as missing) in the summary statistics.
§Some individuals (n = 21; 2.7%) had negative net wealth, largely from mortgage debt. Median
wealth was $161,500.
Alzheimer’s disease;ADL, activity of daily living.
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regression. We found no difference (P > 0.1) in respondent char-
acteristics, including cognitive functioning and other risk factors
of AD, between those who answered 0, 50, or 100 and those who
answered otherwise.
Correlates of Perceived Risk of AD
Multivariate regression results show that several risk factors of
AD are associated with perceived risk of AD (Table 2). For
example, a ﬁve-point increase in the cognitive functioning score
is associated with a 3.8 percentage points (P = 0.0063) lower
perceived risk of AD. Likewise, people who engage in regular
physical activity are likely to have 4.6 percentage points
(P = 0.025) lower perceived risk of AD. Nevertheless, age and
cardiovascular disease indicators are not related to perceived
risk. African Americans are associated with 8.4 percentage points
(P = 0.053) lower perceived risk of AD as compared with non-
Latino whites.
To further examine the interaction effect of age, we conducted
subgroup analyses in two age groups—64 or younger and 65
or older—and found a substantial difference between the two
groups. The most notable difference is the effect of age: in the
younger group, perceived risk increases with age (P = 0.081),
consistent with the increasing risk of AD with aging, but in
the older group, perceived risk decreases with age (P = 0.0031).
Better cognitive functioning (P = 0.012) and regular physical
activity (P = 0.053) are associated with decreased perceived risk
of AD only for the older group. Racial/ethnic difference exists
only among the elderly group in that African Americans
have a lower perceived risk of AD by 16.9 percentage points
(P = 0.0027) than non-Latino whites. The overall coefﬁcients of
each subgroup are statistically different from the coefﬁcients
from the combined sample.
Sensitivity Analysis
We explored the possibility that individual’s perceived risk of AD
may have been based on their perception of decline in memory,
which is accepted as a critical precursor of dementia [24,33].
People who reported that their memory declined over the last 2
years were likely to report 11 percentage points higher perceived
risk of AD (P < 0.001). The inclusion of self-rated memory
decline improved the overall explanatory power of the model,
indicated by the R-square, by 0.03, although the R-square of
the model is still very small, 0.07.
A potential confounding factor in the relationship between
risk factors and perceived risk of AD might be longevity expec-
tation. That is, people who have longer life expectancy may have
higher perceived risk of AD; conversely, people with multiple
comorbidities may have a shorter longevity expectation, and
thus, may have a low perceived risk of AD. To examine this
hypothesis, we included an additional covariate, subjective
longevity expectation. The results, however, are similar to prior
models. Furthermore, high longevity expectation is associated
with decreased level of perceived risk of AD (P = 0.06), conﬁrm-
ing that people do not relate aging directly to risk of AD.
Preference for Preventing AD
Perceived risk is associated with a stronger preference for
preventing AD, which is measured by WTP for a hypothetical
drug preventing AD (Table 3). Individuals with better cognitive
functioning (P = 0.010) and those without ADL limitations
(P = 0.019) have a stronger preference for AD prevention. As
expected, individuals with higher levels of wealth are willing
to pay more (P = 0.0048). An alternative speciﬁcation of wealth
and income, using dummy variables reﬂecting each quartile,
produced similar results (i.e., increasing WTP with wealth; no
income effect). None of the known risk factors for AD is signiﬁ-
cant. The results are similar in the regression, without perceived
risk of AD, as a covariate (Table 3).
Discussion
Older adults appear to formulate their perceived risk of AD in
relation to some known risk factors for AD, such as cognitive
functioning, perceived memory decline, and level of physical
activity. Nevertheless, we found that age is not associated with
perceived risk of AD in the overall sample and is inversely related
to perceived risk of AD among people aged 65 or older, suggest-
ing that individuals may not link aging to an increased risk of
AD. Consistently, people with higher longevity expectation are
likely to report lower levels of perceived risk for AD. Given the
fact that age is one of the most important risk factors for AD and
the actual risk of AD increases exponentially with age [14,26],
our ﬁndings suggest a lack of knowledge about risk factors for
AD among older adults. Similarly, perceived risk is not related to
the presence of cardiovascular disease or diabetes which is poten-
tially modiﬁable risk factors for AD. Taken together, our ﬁndings
suggest that individuals’ perceived risk of AD may not be asso-
ciated with objective risk of AD, and thus, may not be accurate.
What would be the reasons for the lack of concordance
between known risk factors and perceived risk of AD? One
possibility is that people may not have an appropriate level of
knowledge about speciﬁc risk factors of AD [15,16] and may not
process dementia risk factor information based on scientiﬁc evi-
dence [16]. Another reason might be that measures of risk factors
in the data are crude. For example, if well controlled, cardiovas-
cular disease risk factors may not be perceived as a disease or
risk factors for AD at all. In fact, in our data, 92% of people who
had diabetes reported that their diabetes was well controlled.
Likewise, people who had a memory-related disease because of
stroke were not included in the study sample.
The overall variation in perceived risk explained by known
risk factors and demographic factors in our model is very small
(R-squared = 0.04), suggesting that only a small amount of varia-
tion in risk perception was explained by the observed factors.
There are many potential explanations. First, the available data
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used in the analysis are limited in their ability to capture the full
range of information people use in formulating risk perception of
AD. Second, the measure of risk perception may not perform
well in capturing the true level of perceived risk of AD. People
may have problems answering risk perception questions which
involve probability with a 0–100 scale [34,35]. Third, perceived
risk of AD may not be in fact based on either observed or
unobserved objective risk factors. To better understand the
process and type of information individuals use to formulate risk
perception on AD, a more in-depth study may be needed.
Given the lack of explanatory power of the known risk
factors on perceived risk of AD, it is not surprising to ﬁnd that
none of the known risk factors explain preference for AD pre-
vention. Furthermore, both better cognitive test performance and
better physical functioning are strong positive predictors of pref-
erences for AD prevention. There are several possible explana-
tions for the discrepancy. First, more cognitively active persons
may have strong preference for avoiding cognitive impairment
and hence are willing to pay more to prevent it. Second, cogni-
tive status may be a proxy for other unobserved factors that
are associated with greater awareness about AD and its conse-
quences. Third, people with higher cognitive functioning may
have a greater capacity to weight multiple factors when estimat-
ing the beneﬁt of treatment. Fourth, people with a lower level of
cognitive functioning may not value cognitive health as much
as those who have better cognitive functioning because of other
impending issues such as other physical health problems or ﬁnan-
cial hardships.
While these potential pathways merit further investigation in
future studies, our ﬁndings indicate that demands for AD pre-
vention may be inversely related to objective needs and suggest a
potential discrepancy between need and demand for preventive
care for AD. Although it is yet unknown whether WTP for AD
prevention would conﬁrm to the realized preventive behavior
when the actual preventive option is available, evidence from
cancer suggests a strong correlation between stated preferences
Table 3 Preference for preventing AD: multivariate linear regression
Dependent variable: preference for AD prevention with six categories (1–6), each indicating WTP (per month) of <$5, $5–25, $25–100, $100–250, $250–1000,
and $1000 for a drug preventing AD
(A) With perceived risk of AD
N = 715
(B) Without perceived risk of AD
N = 743
Coefﬁcient (SE) P-value Coefﬁcient (SE) P-value
Perceived risk of AD (0–100) 0.01‡ <0.001
(0.002)
Known risk factors of AD
Age -0.01* 0.10 -0.01 0.14
(0.01) (0.01)
Cognitive functioning (0–27) 0.03‡ 0.01 0.03† 0.01
(0.01) (0.01)
Physical activity 0.02 0.85 0.02 0.79
(0.09) (0.09)
Stroke 0.07 0.70 0.16 0.39
(0.18) (0.18)
Heart attack -0.08 0.83 -0.27 0.49
(0.36) (0.39)
Diabetes 0.16 0.18 0.19 0.10
(0.12) (0.12)
Any ADL limitation -0.34† 0.02 -0.28* 0.06
(0.15) (0.15)
Other sociodemographic factors
Female -0.07 0.46 -0.01 0.93
(0.10) (0.10)
Race/ethnicity (ref: non-Hispanic white)
Black 0.14 0.40 0.02 0.93
(0.16) (0.16)
Hispanic -0.33 0.11 -0.39* 0.08
(0.21) (0.22)
Other race 0.70 0.11 0.55 0.18
(0.44) (0.40)
Education (ref: high school graduate)
Less than high school -0.08 0.54 -0.13 0.27
(0.13) (0.12)
Some college -0.07 0.49 -0.05 0.60
(0.11) (0.11)
Married 0.13 0.26 0.16 0.13
(0.11) (0.11)
Household wealth (/100 k) 0.005‡ 0.005 0.005† 0.02
(0.002) (0.002)
Household income (/100 k) 0.08 0.24 0.06 0.38
(0.07) (0.06)
Prescription drug coverage 0.15 0.18 0.14 0.22
(0.11) (0.11)
Constant 3.64‡ <0.001 3.75‡ <0.001
(0.53) (0.52)
R-squared 0.10 0.08
*P < 0.1, †P < 0.05, ‡P < 0.01.
Coefﬁcient (robust standard errors).
AD,Alzheimer’s disease;ADL, activity of daily living; SE, standard error;WTP, willingness to pay.
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for and actual use of certain preventive screening [36,37]. Thus,
our ﬁndings suggest that, when effective preventive treatments
for AD are developed in the future, the treatments will be sought
by people who are more cognitively intact and are less likely to
develop AD than those who are more vulnerable to the develop-
ment of AD. This ﬁnding has signiﬁcant public health impli-
cations, and needs to be addressed in health education and
intervention programs to achieve better efﬁciency and equity of
health-care resource use.
The difference in perceived risk by race/ethnicity also suggests
a potential discordance between needs and demands for AD care.
The lower level of perceived risk of AD among African Ameri-
cans, as compared with non-Latino whites, is alarming given that
the actual risk of AD among African Americans is not lower than
among non-Latino whites [38–41]. This may be because of lower
levels of knowledge or sources of information regarding AD
among African Americans [15]. Lower level of perceived risk,
despite of equal or higher level of objective risk among African
Americans, may lead to inadequate levels of preventive behavior,
such as seeking professional help in an early stage of the disease.
Not surprisingly, African Americans are underserved with regard
to dementia care, often receiving services later in the disease
course than non-Latino whites [42].
In interpreting our results about preferences for AD preven-
tion, it is important not to interpret the WTP value as the actual
amount respondents were willing to pay or to attempt to
compare WTP values across studies. First, the values may reﬂect
“starting point bias,” in which individuals answer differently
depending on which dollar amount is presented ﬁrst. In our
study, everyone was given the value $100 ﬁrst in the questions
asking about WTP for AD prevention and $100 was the most
common response. To address potential starting point bias, we
treated WTP as an ordinal variable (0–6) reﬂecting relative pref-
erence instead of coding the value as a cardinal variable reﬂecting
the amount of money willing to paid. Analyzed this way, use of
a different starting point might not have changed the results of
our study. Second, the hypothetical treatment used to measure
preference for AD prevention was not a feasible AD prevention
option under current technology. The value individuals are
willing to pay when available prevention options, which are
likely to involve risks of adverse side effects, are used might be
different from the amount willing to pay for an imaginary drug.
It is important to note what this study does not do. Some
questions of interest could not be addressed because relevant data
are not available in the HRS. First, we were not able to examine
whether disease awareness through personal experience with
relatives or friends with AD would affect individuals’ perceived
risk. Second, we were not able to evaluate individuals’ knowledge
about prevention and treatment options on risk perception and
prevention preference. Knowledge about AD may inﬂuence how
accurately individuals translate known risk factors into personal
risk and thus would affect individuals’ perception of the risk and
prevention preference. Third, we were not able to validate how
well individuals’ perceived risk predicts actual risk because actual
risk is unknown. Although validation of subjective perception of
AD risk is an important question to be answered by collecting
more extensive data in another study, here we used available data
to examine this link in an indirect way by exploring whether
perceived risk of AD is explained by known risk factors of AD and
other measurable individual characteristics.
Our study has several limitations, largely from the limited
information available in the data, as described above. First, we
did not have information about family background or genetic
risk factors, such as the apolipoprotein E-e4 allele. Genetic
predisposition is known to explain a signiﬁcant proportion of
variations in AD incidence [43]. A large part of the unexplained
variation in perceived risk may have been based on family back-
ground that individuals may take into account, but was not
captured by the survey questions. Second, we did not investigate
the pathways of how people formulate their own risk of AD. The
way known risk factors of AD, let alone other personalized
information, may be linked to the perceived AD risk is complex,
and we could not tease apart the potential pathways in the
present study. Third, the 0 to 100 probability scale used to
measure perceived risk may not be the best way to capture true
perceived risk among older adults. Nevertheless, we found that
the likelihood of providing simpliﬁed answers (e.g., 0, 50, and
100) were not associated with risk factors of AD included in the
model, and thus, measurement error of this type does not seem to
have inﬂuenced our estimates. Fourth, the WTP approach con-
siders only preference, not an individual’s actual preventive
behavior. Tests of how closely stated preference translates into
actual behavior, particularly in the context of AD, requires
further information not available in the data.
Findings from our study, and related previous studies, suggest
some issues to be further addressed. First, future research needs
to investigate the process and type of information people use to
formulate perceived risk of AD, particularly the link between
knowledge about AD risk factors and perceived personal risk for
AD. One way to investigate this would be comparing perceived
risk of AD before and after providing information on AD (e.g.,
risk factors and prevention options). Awareness of the disease
through personal experience could be measured by asking if the
respondent knows someone personally and whether the person is
genetically related or not; further, this information could be
linked with perceived risk of AD to assess whether individuals
process personal information correctly. Second, perceived risk of
AD measure can be validated against actual incidence using
prospective data. Observable risk factors for AD in our data are
limited; people may use other information in estimating their
risk for AD. Perhaps individuals’ perceived risk does actually
conform to their actual risk more closely than available data
would suggest. Third, the underlying reasons for the discrepancy
between objective risk factors and perceived risk of AD need to
be better understood.
In conclusion, older adults’ perceived risk of AD is related to
some risk factors of AD and their preference for AD prevention
corresponds to the perceived risk of AD. A large part of the
variation in perceived risk is unexplained by known risk factors
and individual characteristics, suggesting that more information
about disease awareness through the personal experiences is
needed to understand how people formulate personal risk of AD.
On the other hand, preference for preventive care for AD does
not seem to reﬂect the objective need for prevention. The sources
of discrepancy between need and demand for AD preventive care
should be better understood to help people who are at higher risk
of developing AD engage in preventive behavior at earlier stages
of cognitive decline. Similarly, lower level of perceived risk of AD
among African Americans suggests that the existing disparity in
AD treatment by race/ethnicity [44,45] might be exacerbated
because of lower preference for prevention or less engagement
in preventive behavior that could help delay onset of AD. Thus,
it is important to address the racial/ethnic disparity in the per-
ceived risk of AD by designing and implementing prevention
and education program relevant to varied racial/ethnic groups.
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